Lyell Immunopharma (LYEL) Stock Forecast, Price Target & Predictions
LYEL Stock Forecast
Lyell Immunopharma stock forecast is as follows: an average price target of $6.67 (represents a 425.20% upside from LYEL’s last price of $1.27) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
LYEL Price Target
The average price target for Lyell Immunopharma (LYEL) is $6.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $1.00. This represents a potential 425.20% upside from LYEL's last price of $1.27.
LYEL Analyst Ratings
According to 3 Wall Street analysts, Lyell Immunopharma's rating consensus is 'Hold'. The analyst rating breakdown for LYEL stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 3 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Lyell Immunopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 30, 2024 | Geoff Meacham | Bank of America Securities | $1.00 | $0.95 | 5.47% | -21.26% |
| Nov 14, 2022 | - | Morgan Stanley | $7.00 | $4.53 | 54.53% | 451.18% |
| May 24, 2022 | - | Goldman Sachs | $12.00 | $4.01 | 199.25% | 844.88% |
The latest Lyell Immunopharma stock forecast, released on Oct 30, 2024 by Geoff Meacham from Bank of America Securities, set a price target of $1.00, which represents a 5.47% increase from the stock price at the time of the forecast ($0.95), and a -21.26% decrease from LYEL last price ($1.27).
Lyell Immunopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $1.00 | $1.00 | $1.00 |
| Last Closing Price | $1.27 | $1.27 | $1.27 |
| Upside/Downside | -21.26% | -21.26% | -21.26% |
In the current month, the average price target of Lyell Immunopharma stock is $1.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -21.26% decrease as opposed to Lyell Immunopharma's last price of $1.27. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 28, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Jun 27, 2024 | H.C. Wainwright | - | Neutral | Downgrade |
| Nov 14, 2022 | Morgan Stanley | - | Equal-Weight | Downgrade |
| Nov 11, 2022 | Goldman Sachs | Buy | Neutral | Downgrade |
| May 24, 2022 | Goldman Sachs | Buy | Buy | Hold |
Lyell Immunopharma's last stock rating was published by H.C. Wainwright on Oct 28, 2024. The company gave LYEL a "Neutral" rating, the same as its previous rate.
Lyell Immunopharma Financial Forecast
Lyell Immunopharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $27.00K | $65.00K | $48.39K | $3.00K | $35.74M | $553.00K | $2.82M | $2.75M | $2.63M |
| Avg Forecast | $20.25K | $18.81K | $17.47K | $16.22K | $15.07K | $14.00K | $3.25K | $1.00K | $3.25K | $6.25K | $18.00K | $-17.50K | $16.13M | $1.80M | $17.87M | $776.50K | $2.64M | $2.88M | $2.31M |
| High Forecast | $20.25K | $18.81K | $17.47K | $16.22K | $15.07K | $14.00K | $3.25K | $1.00K | $6.47K | $6.25K | $18.00K | $-17.50K | $16.13M | $1.80M | $17.87M | $776.50K | $2.64M | $2.88M | $2.31M |
| Low Forecast | $20.25K | $18.81K | $17.47K | $16.22K | $15.07K | $14.00K | $3.25K | $1.00K | $19.00 | $6.25K | $18.00K | $-17.50K | $16.13M | $1.80M | $17.87M | $776.50K | $2.64M | $2.88M | $2.31M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.50% | -3.71% | 0.00% | 0.00% | 2.00% | 0.71% | 1.07% | 0.96% | 1.14% |
Lyell Immunopharma's average Quarter revenue forecast for Sep 23 based on 1 analysts is $6.25K, with a low forecast of $6.25K, and a high forecast of $6.25K. LYEL's average Quarter revenue forecast represents a -76.85% decrease compared to the company's last Quarter revenue of $27.00K (Jun 23).
Lyell Immunopharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-57.92M | $-47.53M | $-3.36K | $-56.82M | $-33.09M | $-64.39M | $-79.14M | $-44.78M | $-59.59M |
| Avg Forecast | $-20.25K | $-18.81K | $-17.47K | $-16.22K | $-15.07K | $-14.00K | $-3.25K | $-1.00K | $-3.25K | $-6.25K | $-18.00K | $17.50K | $-16.13M | $-1.80M | $-17.87M | $-65.75M | $-2.64M | $-2.88M | $-70.81M |
| High Forecast | $-20.25K | $-18.81K | $-17.47K | $-16.22K | $-15.07K | $-14.00K | $-3.25K | $-1.00K | $-19.00 | $-6.25K | $-18.00K | $17.50K | $-16.13M | $-1.80M | $-17.87M | $-52.60M | $-2.64M | $-2.88M | $-56.64M |
| Low Forecast | $-20.25K | $-18.81K | $-17.47K | $-16.22K | $-15.07K | $-14.00K | $-3.25K | $-1.00K | $-6.47K | $-6.25K | $-18.00K | $17.50K | $-16.13M | $-1.80M | $-17.87M | $-78.90M | $-2.64M | $-2.88M | $-84.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 3217.78% | -2715.94% | 0.00% | 31.56% | 1.85% | 0.98% | 29.95% | 15.56% | 0.84% |
undefined analysts predict LYEL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lyell Immunopharma's previous annual EBITDA (undefined) of $NaN.
Lyell Immunopharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-63.89M | $-132.63M | $2.44M | $-74.07M | $-35.38M | $-67.71M | $-83.38M | $-48.60M | $-62.38M |
| Avg Forecast | $-58.74M | $-53.63M | $-56.19M | $-52.36M | $-54.91M | $-51.08M | $-50.44M | $-56.19M | $-58.74M | $-61.81M | $-67.04M | $-65.76M | $-58.10M | $-79.45M | $-55.97M | $-70.49M | $-69.07M | $-120.04M | $-74.38M |
| High Forecast | $-58.74M | $-53.63M | $-56.19M | $-52.36M | $-54.91M | $-45.97M | $-50.44M | $-56.19M | $-50.35M | $-61.81M | $-67.04M | $-65.76M | $-58.10M | $-79.45M | $-55.97M | $-56.40M | $-69.07M | $-120.04M | $-59.51M |
| Low Forecast | $-58.74M | $-53.63M | $-56.19M | $-52.36M | $-54.91M | $-58.74M | $-50.44M | $-56.19M | $-72.73M | $-61.81M | $-67.04M | $-65.76M | $-58.10M | $-79.45M | $-55.97M | $-84.59M | $-69.07M | $-120.04M | $-89.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.95% | 2.02% | -0.04% | 0.93% | 0.63% | 0.96% | 1.21% | 0.40% | 0.84% |
Lyell Immunopharma's average Quarter net income forecast for Mar 23 is $-65.76M, with a range of $-65.76M to $-65.76M. LYEL's average Quarter net income forecast represents a -2796.83% decrease compared to the company's last Quarter net income of $2.44M (Dec 22).
Lyell Immunopharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $19.03M | $19.28M | $26.35K | $26.08M | $30.45M | $34.42M | $31.87M | $21.24M | $19.11M |
| Avg Forecast | $2.39M | $2.22M | $2.06M | $1.92M | $1.78M | $1.65M | $383.91K | $118.13K | $383.91K | $738.29K | $2.13M | $-2.07M | $1.91B | $212.63M | $2.11B | $91.73M | $312.16M | $339.91M | $273.35M |
| High Forecast | $2.39M | $2.22M | $2.06M | $1.92M | $1.78M | $1.65M | $383.91K | $118.13K | $764.64K | $738.29K | $2.13M | $-2.07M | $1.91B | $212.63M | $2.11B | $91.73M | $312.16M | $339.91M | $273.35M |
| Low Forecast | $2.39M | $2.22M | $2.06M | $1.92M | $1.78M | $1.65M | $383.91K | $118.13K | $2.24K | $738.29K | $2.13M | $-2.07M | $1.91B | $212.63M | $2.11B | $91.73M | $312.16M | $339.91M | $273.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 8.95% | -9.33% | 0.00% | 0.12% | 0.01% | 0.38% | 0.10% | 0.06% | 0.07% |
Lyell Immunopharma's average Quarter SG&A projection for Sep 23 is $738.29K, based on 1 Wall Street analysts, with a range of $738.29K to $738.29K. The forecast indicates a -96.12% fall compared to LYEL last annual SG&A of $19.03M (Jun 23).
Lyell Immunopharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.26 | $-0.53 | $0.01 | $-0.30 | $-0.14 | $-0.28 | $-0.35 | $-0.20 | $-1.46 |
| Avg Forecast | $-0.23 | $-0.21 | $-0.22 | $-0.20 | $-0.21 | $-0.20 | $-0.20 | $-0.22 | $-0.23 | $-0.24 | $-0.26 | $-0.26 | $-0.23 | $-0.31 | $-0.22 | $-0.28 | $-0.27 | $-0.47 | $-0.38 |
| High Forecast | $-0.23 | $-0.21 | $-0.22 | $-0.20 | $-0.21 | $-0.18 | $-0.20 | $-0.22 | $-0.20 | $-0.24 | $-0.26 | $-0.26 | $-0.23 | $-0.31 | $-0.22 | $-0.28 | $-0.27 | $-0.47 | $-0.38 |
| Low Forecast | $-0.23 | $-0.21 | $-0.22 | $-0.20 | $-0.21 | $-0.23 | $-0.20 | $-0.22 | $-0.28 | $-0.24 | $-0.26 | $-0.26 | $-0.23 | $-0.31 | $-0.22 | $-0.28 | $-0.27 | $-0.47 | $-0.38 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.99% | 2.06% | -0.04% | 0.96% | 0.64% | 1.01% | 1.29% | 0.43% | 3.89% |
According to 1 Wall Street analysts, Lyell Immunopharma's projected average Quarter EPS for Mar 23 is $-0.26, with a low estimate of $-0.26 and a high estimate of $-0.26. This represents a -2701.01% decrease compared to LYEL previous annual EPS of $0.01 (Dec 22).
Lyell Immunopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
| STTK | Shattuck Labs | $1.16 | $12.00 | 934.48% | Hold |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| NKTX | Nkarta | $3.23 | $21.60 | 568.73% | Buy |
| LYEL | Lyell Immunopharma | $1.27 | $6.67 | 425.20% | Hold |
| SANA | Sana Bio | $3.76 | $12.00 | 219.15% | Buy |
| NUVB | Nuvation Bio | $2.29 | $6.75 | 194.76% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| MRUS | Merus | $51.23 | $77.13 | 50.56% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.82 | $70.14 | 23.44% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
LYEL Forecast FAQ
Is Lyell Immunopharma a good buy?
No, according to 3 Wall Street analysts, Lyell Immunopharma (LYEL) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of LYEL's total ratings.
What is LYEL's price target?
Lyell Immunopharma (LYEL) average price target is $6.67 with a range of $1 to $12, implying a 425.20% from its last price of $1.27. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Lyell Immunopharma stock go up soon?
According to Wall Street analysts' prediction for LYEL stock, the company can go up by 425.20% (from the last price of $1.27 to the average price target of $6.67), up by 844.88% based on the highest stock price target, and down by -21.26% based on the lowest stock price target.
Can Lyell Immunopharma stock reach $2?
LYEL's average twelve months analyst stock price target of $6.67 supports the claim that Lyell Immunopharma can reach $2 in the near future.
What is Lyell Immunopharma's current price target trend?
1 Wall Street analyst forecast a $1 price target for Lyell Immunopharma (LYEL) this month, down -21.26% from its last price of $1.27. Compared to the last 3 and 12 months, the average price target decreased by -21.26% and decreased by -21.26%, respectively.
What are Lyell Immunopharma's analysts' financial forecasts?
Lyell Immunopharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $33.32K (high $33.32K, low $33.32K), average EBITDA is $-33.315K (high $-33.315K, low $-33.315K), average net income is $-213M (high $-208M, low $-220M), average SG&A $3.94M (high $3.94M, low $3.94M), and average EPS is $-0.833 (high $-0.812, low $-0.863). LYEL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $72.74K (high $72.74K, low $72.74K), average EBITDA is $-72.744K (high $-72.744K, low $-72.744K), average net income is $-221M (high $-221M, low $-221M), average SG&A $8.59M (high $8.59M, low $8.59M), and average EPS is $-0.865 (high $-0.865, low $-0.865).
Did the LYEL's actual financial results beat the analysts' financial forecasts?
Based on Lyell Immunopharma's last annual report (Dec 2022), the company's revenue was $84.68M, beating the average analysts forecast of $36.58M by 131.53%. Apple's EBITDA was $-165M, beating the average prediction of $-102M by 62.58%. The company's net income was $-183M, missing the average estimation of $-264M by -30.64%. Apple's SG&A was $117.31M, missing the average forecast of $4.32B by -97.28%. Lastly, the company's EPS was $-0.74, missing the average prediction of $-1.035 by -28.52%. In terms of the last quarterly report (Jun 2023), Lyell Immunopharma's revenue was $27K, beating the average analysts' forecast of $18K by 50.00%. The company's EBITDA was $-57.92M, beating the average prediction of $-18K by 321677.78%. Lyell Immunopharma's net income was $-63.89M, missing the average estimation of $-67.042M by -4.70%. The company's SG&A was $19.03M, beating the average forecast of $2.13M by 794.99%. Lastly, the company's EPS was $-0.26, missing the average prediction of $-0.263 by -0.95%